Washington University School of Medicine

Digital Commons@Becker
Open Access Publications
2010

Improved survival with ipilimumab in patients with metastatic
melanoma
Gerald P. Linette
Washington University School of Medicine in St. Louis

et al

Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs

Recommended Citation
Linette, Gerald P. and et al, ,"Improved survival with ipilimumab in patients with metastatic melanoma."
The New England Journal of Medicine. 363,8. 711-23. (2010).
https://digitalcommons.wustl.edu/open_access_pubs/3545

This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been
accepted for inclusion in Open Access Publications by an authorized administrator of Digital Commons@Becker.
For more information, please contact vanam@wustl.edu.

new england
journal of medicine
The

established in 1812

august 19, 2010

vol. 363

no. 8

Improved Survival with Ipilimumab in Patients
with Metastatic Melanoma
F. Stephen Hodi, M.D., Steven J. O’Day, M.D., David F. McDermott, M.D., Robert W. Weber, M.D.,
Jeffrey A. Sosman, M.D., John B. Haanen, M.D., Rene Gonzalez, M.D., Caroline Robert, M.D., Ph.D.,
Dirk Schadendorf, M.D., Jessica C. Hassel, M.D., Wallace Akerley, M.D., Alfons J.M. van den Eertwegh, M.D., Ph.D.,
Jose Lutzky, M.D., Paul Lorigan, M.D., Julia M. Vaubel, M.D., Gerald P. Linette, M.D., Ph.D., David Hogg, M.D.,
Christian H. Ottensmeier, M.D., Ph.D., Celeste Lebbé, M.D., Christian Peschel, M.D., Ian Quirt, M.D.,
Joseph I. Clark, M.D., Jedd D. Wolchok, M.D., Ph.D., Jeffrey S. Weber, M.D., Ph.D., Jason Tian, Ph.D.,
Michael J. Yellin, M.D., Geoffrey M. Nichol, M.B., Ch.B., Axel Hoos, M.D., Ph.D., and Walter J. Urba, M.D., Ph.D.

A bs t r ac t
Background

An improvement in overall survival among patients with metastatic melanoma has
been an elusive goal. In this phase 3 study, ipilimumab — which blocks cytotoxic
T-lymphocyte–associated antigen 4 to potentiate an antitumor T-cell response —
administered with or without a glycoprotein 100 (gp100) peptide vaccine was compared with gp100 alone in patients with previously treated metastatic melanoma.
Methods

A total of 676 HLA-A*0201–positive patients with unresectable stage III or IV melanoma, whose disease had progressed while they were receiving therapy for metastatic disease, were randomly assigned, in a 3:1:1 ratio, to receive ipilimumab plus
gp100 (403 patients), ipilimumab alone (137), or gp100 alone (136). Ipilimumab, at a
dose of 3 mg per kilogram of body weight, was administered with or without gp100
every 3 weeks for up to four treatments (induction). Eligible patients could receive
reinduction therapy. The primary end point was overall survival.
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Results

The median overall survival was 10.0 months among patients receiving ipilimumab
plus gp100, as compared with 6.4 months among patients receiving gp100 alone
(hazard ratio for death, 0.68; P<0.001). The median overall survival with ipilimumab
alone was 10.1 months (hazard ratio for death in the comparison with gp100 alone,
0.66; P = 0.003). No difference in overall survival was detected between the ipilimumab groups (hazard ratio with ipilimumab plus gp100, 1.04; P = 0.76). Grade 3
or 4 immune-related adverse events occurred in 10 to 15% of patients treated with
ipilimumab and in 3% treated with gp100 alone. There were 14 deaths related to
the study drugs (2.1%), and 7 were associated with immune-related adverse events.
Conclusions

Ipilimumab, with or without a gp100 peptide vaccine, as compared with gp100 alone,
improved overall survival in patients with previously treated metastatic melanoma.
Adverse events can be severe, long-lasting, or both, but most are reversible with appropriate treatment. (Funded by Medarex and Bristol-Myers Squibb; ClinicalTrials.gov
number, NCT00094653.)
n engl j med 363;8
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T

he incidence of metastatic mela
noma has increased over the past three de
cades,1,2 and the death rate continues to
rise faster than the rate with most cancers.3 The
World Health Organization (WHO) estimates that
worldwide there are 66,000 deaths annually from
skin cancer, with approximately 80% due to melanoma.4 In the United States alone, an estimated
8600 persons died from melanoma in 2009.1 The
median survival of patients with melanoma who
have distant metastases (American Joint Committee on Cancer stage IV) is less than 1 year.5,6
No therapy is approved beyond the first-line therapy for metastatic melanoma, and enrollment in
a clinical trial is the standard of care. No therapy
has been shown in a phase 3, randomized, controlled trial to improve overall survival in patients
with metastatic melanoma.6-9
Regulatory pathways that limit the immune
response to cancer are becoming increasingly
well characterized. Cytotoxic T-lymphocyte–associated antigen 4 (CTLA-4) is an immune checkpoint molecule that down-regulates pathways of
T-cell activation.10 Ipilimumab, a fully human
monoclonal antibody (IgG1) that blocks CTLA-4
to promote antitumor immunity,11-14 has shown
activity in patients with metastatic melanoma
when it has been used as monotherapy in phase 2
studies.15-17 Ipilimumab has also shown activity
when combined with other agents,18,19 including
cancer vaccines.20,21 One well-studied cancer vaccine comprises HLA-A*0201–restricted peptides
derived from the melanosomal protein, glycoprotein 100 (gp100). Monotherapy with this vaccine induces immune responses but has limited
antitumor activity.22 However, the results of a
recent study suggest that gp100 may improve the
efficacy of high-dose interleukin-2 in patients
with metastatic melanoma.23 With no accepted
standard of care, gp100 was used as an active
control for our phase 3 study, which evaluated
whether ipilimumab with or without gp100 improves overall survival, as compared with gp100
alone, among patients with metastatic melanoma who had undergone previous treatment.
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peutic regimen containing one or more of the
following: dacarbazine, temozolomide, fotemustine, carboplatin, or interleukin-2. Other inclusion criteria were age of at least 18 years; life expectancy of at least 4 months; Eastern Cooperative
Oncology Group (ECOG) performance status of 0
(fully active, able to carry on all predisease performance without restriction) or 1 (restricted in
physically strenuous activity but ambulatory and
able to carry out work of a light or sedentary nature, such as light housework or office work)24;
positive status for HLA-A*0201; normal hematologic, hepatic, and renal function; and no system
ic treatment in the previous 28 days. Exclusion
criteria were any other cancer from which the
patient had been disease-free for less than 5 years
(except treated and cured basal-cell or squamouscell skin cancer, superficial bladder cancer, or
treated carcinoma in situ of the cervix, breast, or
bladder); primary ocular melanoma; previous receipt of anti–CTLA-4 antibody or cancer vaccine;
autoimmune disease; active, untreated metastases
in the central nervous system; pregnancy or lactation; concomitant treatment with any nonstudy
anticancer therapy or immunosuppressive agent;
or long-term use of systemic corticosteroids.
The protocol was approved by the institution
al review board at each participating institution
and was conducted in accordance with the ethical principles originating from the Declaration
of Helsinki and with Good Clinical Practice as
defined by the International Conference on Harmonization. All patients (or their legal representatives) gave written informed consent before
enrollment.
Study Design and Treatment

In this randomized, double-blind, phase 3 study,
we enrolled patients at 125 centers in 13 countries in North America, South America, Europe,
and Africa. Between September 2004 and August
2008, patients were randomly assigned to one of
three study groups, with stratification according
to baseline metastasis stage (M0, M1a, or M1b
vs. M1c, classified according to the tumor–node–
metastasis [TNM] categorization for melanoma
of the American Joint Committee on Cancer), and
Me thods
receipt or nonreceipt of previous interleukin-2
Patients
therapy. The full original protocol, a list of amendPatients were eligible for inclusion in the study if ments, and the final protocol, as well as the stathey had a diagnosis of unresectable stage III or tistical analysis plan, are available with the full
IV melanoma and had received a previous thera- text of this article at NEJM.org.
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Patients were randomly assigned, in a 3:1:1
ratio, to treatment with an induction course of
ipilimumab, at a dose of 3 mg per kilogram of
body weight, plus a gp100 peptide vaccine; ipi
limumab plus gp100 placebo; or gp100 plus ipi
limumab placebo — all administered once every
3 weeks for four treatments. In the vaccine
groups, patients received two modified HLAA*0201–restricted peptides, injected subcutaneously as an emulsion with incomplete Freund’s
adjuvant (Montanide ISA-51): a gp100:209217(210M) peptide, 1 mg injected in the right
anterior thigh, and a gp100:280-288(288V) peptide, 1 mg injected in the left anterior thigh.
Peptide injections were given immediately after
a 90-minute intravenous infusion of ipilimumab
or placebo. Treatment began on day 1 of week 1,
and if there were no toxic effects that could not
be tolerated, no rapidly progressive disease, and
no significant decline in performance status,
patients received an additional treatment during
weeks 4, 7, and 10. Patients in whom new lesions
developed or baseline lesions grew were allowed
to receive additional treatments to complete induction. Patients with stable disease for 3 months’
duration after week 12 or a confirmed partial or
complete response were offered additional courses
of therapy (reinduction) with their assigned treatment regimen if they had disease progression.
The original primary end point was the best
overall response rate (i.e., the proportion of patients with a partial or complete response). The
primary end point was amended to overall survival (with the amendment formally approved on
January 15, 2009) in the ongoing blinded study,
on the basis of phase 2 data and in alignment
with another ongoing phase 3 trial of ipilimu
mab involving patients with metastatic melanoma.25 The primary comparison in overall survival was between the ipilimumab-plus-gp100
group and the gp100-alone group. Prespecified
secondary end points included a comparison of
overall survival between the ipilimumab-alone
and the gp100-alone groups and between the
two ipilimumab groups, the best overall response
rate, the duration of response, and progressionfree survival. Subgroup comparisons of overall
survival were performed across five prespecified
categories: metastasis stage (M0, M1a, or M1b
vs. M1c), receipt or nonreceipt of previous interleukin-2 therapy, baseline levels of serum lactate
dehydrogenase (less than or equal to the upper
limit of the normal range vs. higher than the
n engl j med 363;8

upper limit of the normal range), age (<65 years
vs. ≥65 years), and sex.
The trial was designed jointly by the senior
academic authors and the sponsors, Medarex
and Bristol-Myers Squibb. Data were collected by
the sponsors and analyzed in collaboration with
the senior academic authors, who vouch for the
completeness and accuracy of the data and
analyses and for the conformance of this report
to the protocol, as amended. An initial draft of
the manuscript was prepared by six of the academic authors in collaboration with the sponsor
and a professional medical writer paid by the
sponsor. All the authors contributed to subsequent drafts and made the decision to submit
the manuscript for publication. All the authors
signed a confidentiality disclosure agreement
with the sponsor.
Assessments

For the assessment of a patient’s eligibility, each
patient’s HLA-A*0201 status was determined at a
central laboratory. Patients who met the study
criteria were assigned to receive treatment within
35 days after HLA typing and within 28 days after diagnostic imaging. Computed tomography
with contrast material or magnetic resonance
imaging of the brain, chest, abdomen, pelvis,
and other anatomical regions, as clinically indicated, was performed. Cutaneous lesions were
photographed. Tumor assessments were performed at baseline, and all patients who did not
have documented early disease progression and
who had stable disease or better at week 12 had
confirmatory scans at weeks 16 and 24 and every
3 months thereafter. Tumor responses were determined by the investigators with the use of
modified WHO criteria to evaluate bidimensionally measurable lesions.26
Adverse events were graded according to the
National Cancer Institute’s Common Terminology Criteria for Adverse Events, version 3.0. An
immune-related adverse event was defined as an
adverse event that was associated with exposure
to the study drug and that was consistent with
an immune phenomenon. Protocol guidelines
for the management of immune-related adverse
events included the administration of cortico
steroids (orally or intravenously), a delay in a
scheduled dose, or discontinuation of therapy.15-17 Assigned doses were delayed in the case
of nondermatologic immune-related adverse
events of grade 2 or higher until the event im-
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proved to grade 1 or lower; if the event did not
improve to grade 1 or lower, treatment was discontinued permanently. Monitoring of adverse
events continued for at least 70 days after the
last dose of study drugs had been administered
or until any ongoing event resolved or stabilized.
All patients, including those with low-grade
changes in bowel frequency or stool consistency,
were followed closely. A data and safety monitoring committee provided independent oversight of safety and the risk–benefit ratio.
During the study enrollment, the following
stopping rule was in place: if 10% or more of the
patients in any study treatment group, evaluated
cumulatively every 3 months, had a nondermatologic-related toxic adverse event of grade 3 or
higher that was attributable to the investigational
agents and that could not be alleviated or controlled by appropriate care or corticosteroid therapy within 14 days after the initiation of supportive care or corticosteroid therapy, assignment
of patients to that study group would be suspended until the sponsor and the data and safety
monitoring committee had reviewed the events
and determined the appropriate course of action.
Statistical Analysis

of
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two-sided alpha level of 0.05, with the assumption that ipilimumab alone has the same treatment effect as the combination regimen of ipilimumab plus gp100.
Survival was defined as the time from randomization to death from any cause, and progression-free survival as the time from randomization to documented disease progression or
death. Event-time distributions were estimated
with the use of the Kaplan–Meier method. Cox
proportional-hazards models, stratified according to metastasis status and receipt or nonreceipt of previous interleukin therapy, were used
to estimate hazard ratios and to test for significance of the timing of events. All reported
P values are two-sided, and confidence intervals
are at the 95% level. Survival rates were based on
Kaplan–Meier estimation, and confidence intervals were calculated with the use of the bootstrap method. Descriptive statistics were used
for adverse events.

R e sult s
Patients and Treatment

Among 676 patients enrolled in the study, 403
were randomly assigned to receive ipilimumab
plus gp100, 137 to receive ipilimumab alone, and
136 to receive gp100 alone (control group) (Fig. 1
in the Supplementary Appendix, available at
NEJM.org). Included among these patients were
82 patients who had metastases in the central
nervous system at baseline, of whom 77 received
the study drug. The baseline characteristics of
the patients are shown in Table 1. Efficacy analyses were performed on the intention-to-treat
population, which included all patients who had
undergone randomization (676 patients). The
safety population included all patients who had
undergone randomization and who had received
any amount of study drug (643 patients). A total
of 242 of 403 patients in the ipilimumab-plusgp100 group (60.0%), 88 of 137 in the ipilimu
mab-alone group (64.2%), and 78 of 136 in the
gp100-alone group (57.4%) received all four ipi
limumab doses or placebo infusions. The most
frequent reason for discontinuation of therapy
was disease progression.

The original study sample size of 750 patients
was determined on the basis of the primary end
point of best overall response rate but was revised with the new primary end point of overall
survival. We estimated that with 385 events
(deaths) among a total of 500 patients randomly
assigned to the ipilimumab-plus-gp100 and the
gp100-alone groups, the study would have at
least 90% power to detect a difference in overall
survival, at a two-sided alpha level of 0.05, with
the use of a log-rank test. A total of 481 events
were required in all three groups (assuming that
the events were distributed in a 3:1:1 ratio in the
ipilimumab-plus-gp100, ipilimumab-alone, and
gp100-alone groups, respectively). Therefore, all
patients who were randomly assigned in the
study were to be followed until at least 481 events
had occurred in the study. Enrollment was completed on July 25, 2008, when more than 650 patients had been enrolled. A post hoc power analysis showed that the 219 events observed among
a total of 273 patients randomly assigned to the
ipilimumab-alone and gp100-alone groups pro- Efficacy
vided at least 80% power to detect a difference in All the analyses of the efficacy end points reoverall survival between the two groups, at a ported here were prespecified as per protocol.
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Table 1. Baseline Characteristics of the Patients.*
Ipilimumab
plus gp100
(N = 403)

Ipilimumab
Alone
(N = 137)

gp100 Alone
(N = 136)

Total
(N = 676)

55.6

56.8

57.4

56.2

Male

247 (61.3)

81 (59.1)

73 (53.7)

401 (59.3)

Female

156 (38.7)

56 (40.9)

63 (46.3)

275 (40.7)

0

232 (57.6)

72 (52.6)

70 (51.5)

374 (55.3)

1

166 (41.2)

64 (46.7)

61 (44.9)

291 (43.0)

2

4 (1.0)

1 (0.7)

4 (2.9)

9 (1.3)

3

1 (0.2)

0

0

1 (0.1)

0

0

1 (0.7)

1 (0.1)

M0

5 (1.2)

1 (0.7)

4 (2.9)

10 (1.5)

M1a

37 (9.2)

14 (10.2)

11 (8.1)

62 (9.2)

M1b

76 (18.9)

22 (16.1)

23 (16.9)

121 (17.9)

M1c

285 (70.7)

100 (73.0)

98 (72.1)

483 (71.4)

Variable
Mean age — yr
Sex — no. (%)

ECOG performance status — no. (%)†

Unknown
M stage — no. (%)‡

Lactate dehydrogenase level — no. (%)
≤Upper limit of the normal range

252 (62.5)

84 (61.3)

81 (59.6)

417 (61.7)

>Upper limit of the normal range

149 (37.0)

53 (38.7)

52 (38.2)

254 (37.6)

Unknown

3 (2.2)

5 (0.7)

46 (11.4)

2 (0.5)

15 (10.9)

21 (15.4)

82 (12.1)

Received study drug

42 (10.4)

15 (10.9)

20 (14.7)

77 (11.4)

Had had previous treatment for CNS
metastases

39 (9.7)

15 (10.9)

19 (14.0)

73 (10.8)

Previous systemic therapy for metastatic
disease — no. (%)

403 (100.0)

137 (100.0)

136 (100.0)

676 (100.0)

Previous interleukin-2 therapy — no. (%)

89 (22.1)

32 (23.4)

33 (24.3)

154 (22.8)

CNS metastases at baseline — no. (%)

0

* Percentages may not total 100 because of rounding. CNS denotes central nervous system.
† The Eastern Cooperative Oncology Group (ECOG) status ranges from 0 to 5, with higher scores indicating greater impairment (5 indicates death).
‡ The metastasis (M) stage was classified according to the tumor–node–metastasis (TNM) categorization for melanoma
of the American Joint Committee on Cancer.

Patients were followed for up to 55 months, with
median follow-up times for survival of 21.0
months in the ipilimumab-plus-gp100 group,
27.8 months in the ipilimumab-alone group, and
17.2 months in the gp100-alone group. The median overall survival in the ipilimumab-plusgp100 group was 10.0 months (95% confidence
interval [CI], 8.5 to 11.5), as compared with 6.4
months (95% CI, 5.5 to 8.7) in the gp100-alone
group (hazard ratio for death, 0.68; P<0.001).
The median overall survival in the ipilimumabalone group was 10.1 months (95% CI, 8.0 to
n engl j med 363;8

13.8) (hazard ratio for death with ipilimumab
alone as compared with gp100 alone, 0.66;
P = 0.003). No difference in overall survival was
detected between the two ipilimumab groups
(hazard ratio for death with ipilimumab plus
gp100, 1.04; P = 0.76) (Fig. 1). Analyses of survival showed that the rates of overall survival in
the ipilimumab-plus-gp100 group, the ipilimu
mab-alone group, and the gp100-alone group,
respectively, were 43.6%, 45.6%, and 25.3% at 12
months, 30.0%, 33.2%, and 16.3% at 18 months,
and 21.6%, 23.5%, and 13.7% at 24 months. The
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gp100 group, 2.86 months (95% CI, 2.76 to 3.02) in the ipilimumab-alone
group, and 2.76 months (95% CI, 2.73 to 2.83) in the gp100-alone group.
The rates of progression-free survival at week 12 were 49.1% (95% CI, 44.1
to 53.9) in the ipilimumab-plus-gp100 group, 57.7% (95% CI, 48.9 to 65.5)
in the ipilimumab-alone group, and 48.5% (95% CI, 39.6 to 56.7) in the
gp100-alone group.
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effect of ipilimumab on overall survival was independent of age, sex, baseline serum lactate dehydrogenase levels, metastasis stage of disease,
and receipt or nonreceipt of previous interleukin-2 therapy (Fig. 2).
A 19% reduction in the risk of progression
was noted with ipilimumab plus gp100, as compared with gp100 alone (hazard ratio, 0.81;
P<0.05), and a 36% reduction in risk of progression was seen with ipilimumab alone as compared with gp100 alone (hazard ratio, 0.64;
P<0.001). The reduction in risk with ipilimumab
plus gp100 was less than that with ipilimumab
alone (hazard ratio with ipilimumab plus gp100,
1.25; P = 0.04). The median values for progression-free survival were similar in all groups at
the time of the first assessment of progression
(week 12), after which there was a separation
between the curves (Fig. 1B).
The highest percentage of patients with an
objective response or stable disease was in the
ipilimumab-alone group (Table 2); this group
had a best overall response rate of 10.9% and a
disease control rate (the proportion of patients
with a partial or complete response or stable
disease) of 28.5%. In the ipilimumab-alone group,
9 of 15 patients (60.0%) maintained an objective
response for at least 2 years (26.5 to 44.2 months
[ongoing]), and in the ipilimumab-plus-gp100
group, 4 of 23 patients (17.4%) maintained the
response for at least 2 years (27.9 to 44.4 months
[ongoing]). Neither of the two patients in the
gp100-alone group who had a partial response
maintained the response for 2 years. Responses
to ipilimumab continued to improve beyond week
24: in the ipilimumab-plus-gp100 group, 3 patients with disease progression improved to stable
disease, 3 with stable disease improved to a partial response, and 1 with a partial response improved to a complete response; in the ipilimu
mab-alone group, 2 patients with stable disease
improved to a partial response and 3 with a
partial response improved to a complete response. Among 31 patients given reinduction
therapy with ipilimumab, a partial or complete
response or stable disease was achieved by 21
(Table 2).
Adverse Events

The adverse events reported in the safety population are listed in Table 3. The most common
adverse events related to the study drugs were
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A
Subgroup

Ipi plus gp100

gp100

Hazard Ratio (95% CI)

no. of deaths/no. randomized
All patients
Sex
Male
Female
Age
<65 yr
≥65 yr
M stage at study entry
M0, M1a, M1b
M1c
Baseline LDH
≤ULN
>ULN
Prior use of interleukin-2
Yes
No

306/403

119/136

0.69 (0.56–0.85)

191/247
115/156

66/73
53/63

0.66 (0.50–0.87)
0.72 (0.52–0.99)

219/291
87/112

81/94
38/42

0.70 (0.54–0.90)
0.69 (0.47–1.01)

78/118
228/285

31/38
88/98

0.57 (0.38–0.87)
0.74 (0.58–0.95)

178/252
127/149

66/81
50/52

0.70 (0.53–0.93)
0.71 (0.51–0.98)

68/89
238/314

25/33
94/103

0.78 (0.49–1.24)
0.66 (0.52–0.84)
0.5

1.0

Ipi plus gp100
Better

1.5

gp100
Better

B
Subgroup

Ipi

gp100

Hazard Ratio (95% CI)

no. of deaths/no. randomized
All patients
Sex
Male
Female
Age
<65 yr
≥65 yr
M stage at study entry
M0, M1a, M1b
M1c
Baseline LDH
≤ULN
>ULN
Prior use of interleukin-2
Yes
No

100/137

119/136

0.64 (0.49–0.84)

53/81
47/56

66/73
53/63

0.54 (0.37–0.77)
0.81 (0.55–1.20)

69/95
31/42

81/94
38/42

0.65 (0.47–0.90)
0.61 (0.38–0.99)

21/37
79/100

31/38
88/98

0.47 (0.27–0.82)
0.72 (0.53–0.97)

52/84
48/53

66/81
50/52

0.56 (0.39–0.81)
0.76 (0.51–1.13)

19/32
81/105

25/33
94/103

0.50 (0.28–0.91)
0.69 (0.51–0.93)
0.5

1.0

Ipi
Better

1.5

gp100
Better

Figure 2. Subgroup Analyses of Overall Survival.
The prespecified analyses of overall survival among subgroups of patients, as defined by baseline demographic
characteristics and stratification factors (metastasis [M] stage, classified according to the tumor–node–metastasis
[TNM] categorization for melanoma of the American Joint Committee on Cancer; and receipt or nonreceipt of interleukin-2 therapy), showed that hazard ratios were lower than 1 (indicating a lower risk of death) for each subgroup
in the ipilimumab (Ipi)-plus-glycoprotein 100 (gp100) group as compared with the gp100-alone group (Panel A) and
for each subgroup in the ipilimumab-alone group as compared with the gp100-alone group (Panel B). Hazard ratios
were estimated with the use of unstratified Cox proportional-hazards models. Horizontal lines represent 95% confidence intervals. LDH denotes lactate dehydrogenase, and ULN the upper limit of the normal range.
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Table 2. Best Response to Treatment and Time-to-Event Data.*
Ipilimumab
plus gp100
(N = 403)

Ipilimumab
Alone
(N = 137)

gp100 Alone
(N = 136)

306

100

119

Hazard ratio (95% CI)

0.68 (0.55–0.85)

0.66 (0.51–0.87)

—

P value by log-rank test

<0.001

0.003

—

Response and Time to Event
Overall survival
Total no. of deaths
Comparison with gp100 alone

Comparison with ipilimumab alone
Hazard ratio (95% CI)

1.04 (0.83–1.30)

—

—

P value by log-rank test

0.76

—

—

Evaluation of therapy
Induction
Best overall response — no. (%)
Complete response

1 (0.2)

2 (1.5)

22 (5.5)

13 (9.5)

58 (14.4)

24 (17.5)

13 (9.6)

239 (59.3)

70 (51.1)

89 (65.4)

Partial response
Stable disease
Progressive disease
Not evaluated

0
2 (1.5)

83 (20.6)

28 (20.4)

32 (23.5)

5.7 (3.7–8.4)

10.9 (6.3–17.4)

1.5 (0.2–5.2)

P value for comparison with gp100 alone

0.04

0.001

—

P value for comparison with ipilimumab alone

0.04

—

—
11.0 (6.3–17.5)

Best overall response rate — % (95% CI)

Disease control rate — % (95% CI)†

20.1 (16.3–24.3)

28.5 (21.1–36.8)

P value for comparison with gp100 alone

0.02

<0.001

—

P value for comparison with ipilimumab alone

0.04

—

—

Time to progression — median (95% CI)

2.76 (2.73–2.79)

2.86 (2.76–3.02)

2.76 (2.73–2.83)

Time to response — mean (95% CI)

3.32 (2.91–3.74)

3.18 (2.75–3.60)

2.74 (2.12–3.37)

11.5 (5.4–NR)

NR (28.1–NR)

NR (2.0–NR)

Time to event — mo

Duration of response — median (95% CI)
Reinduction‡
Best overall response — no./total no. (%)
Complete response
Partial response
Stable disease
Progressive disease

0

1/8 (12.5)

0

3/23 (13.0)

2/8 (25.0)

0

12/23 (52.2)

3/8 (37.5)

0

8/23 (34.8)

2/8 (25.0)

1/1 (100.0)

* Of the 143 patients who could not be evaluated for a response, 33 patients did not receive any study drug and 110 patients did not have baseline or week-12 tumor assessments (or both). Percentages may not total 100 because of rounding. NR denotes not reached.
† The disease control rate is the percentage of patients with a partial or complete response or stable disease.
‡ A total of 40 patients (29 in the ipilimumab-plus-gp100 group; 9 in the ipilimumab-alone group, and 2 in the gp100alone group) were given reinduction therapy, but 8 were not included in the efficacy analyses: 3 had major protocol violations and 5 were not eligible owing to the fact that they had had a best overall response of progressive disease during
induction and were given reinduction therapy inadvertently.
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immune-related events, which occurred in approximately 60% of the patients treated with ipilimu
mab and 32% of the patients treated with gp100.
The frequency of grade 3 or 4 immune-related
adverse events was 10 to 15% in the ipilimumab
groups and 3.0% in the gp100-alone group. All
immune-related events occurred during the induction and reinduction periods; the immunerelated adverse events most often affected the
skin and gastrointestinal tract. The median time
to the resolution of immune-related adverse
events of grade 2, 3, or 4 was 6.3 weeks (95% CI,
4.3 to 8.4) in the ipilimumab-plus-gp100 group,
4.9 weeks (95% CI, 3.1 to 6.4) in the ipilimumabalone group, and 3.1 weeks (95% CI, 1.1 to not
reached) in the gp100-alone group.
The most common immune-related adverse
event was diarrhea, which occurred at any grade
in 27 to 31% of the patients in the ipilimumab
groups. After the administration of corticoste
roids, the median time to the resolution of diarrhea of grade 2 or higher was 2.0 weeks for 40
of 44 patients in the ipilimumab-plus-gp100
group and 2.3 weeks for 14 of 15 patients in the
ipilimumab-alone group. In addition to cortico
steroids, 4 patients received infliximab (anti–
tumor necrosis factor α antibody) for diarrhea of
grade 3 or higher or colitis. Among the 94 persons who survived for 2 years, residual effects of
adverse events included those related to injectionsite reactions (16 patients), vitiligo (12), diarrhea
or colitis (e.g., proctocolitis with rectal pain) (4),
and endocrine immune-related adverse events (e.g.,
inflammation of the pituitary) that required
hormone-replacement therapy (8). Ongoing events
in the persons who survived for 2 years included
rash, pruritus, diarrhea, anorexia, and fatigue,
generally of grade 1 or 2 (in 5 to 15% of the
patients) and grade 3 leukocytosis (in one patient). There were 14 deaths related to the study
drugs (2.1%), of which 7 were associated with
immune-related adverse events.

Discussion
This phase 3 study showed that ipilimumab, either alone or with gp100, improved overall survival as compared with gp100 alone in patients
with metastatic melanoma who had undergone
previous treatment. More than 70% of the patients had M1c disease (presence of visceral me-
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tastases) and more than 36% had elevated lactate
dehydrogenase levels, both of which are associated with very poor survival.27,28 The eligibility
criteria for patients in this study included HLAA*0201–positive status, on the basis of the mechanism of action of gp100. However, CTLA-4
blockade by ipilimumab is independent of HLA
status, as indicated by efficacy and safety outcomes in earlier clinical trials that were similar
between HLA-A*0201–positive and HLA-A*0201–
negative patients21 (and unpublished data).
In our study, the efficacy of ipilimumab was
not improved by the addition of gp100. It is unlikely that this is due to a lack of gp100 expression in the tumors, because differentiation antigens have been shown to be strongly expressed
in more than 90% of melanoma tumors, regardless of stage.29 Some studies of adjuvant therapy
for melanoma showed that patients who were administered non–gp100 vaccines had shorter survival than did patients in the control groups.30,31
In contrast, phase 3 trials showed that in subgroups of patients with melanoma, vaccines had
clinical activity when used as either adjuvant
therapy or therapy for metastatic disease.32,33
Cumulative data show that gp100-based vaccines
have immunologic activity, although clinical activity is minimal when gp100 vaccines are administered as monotherapy.22 In a randomized,
phase 3 study involving patients with metastatic
melanoma, a significant improvement in progression-free survival and response rate, and a
nonsignificant improvement in overall survival,
were seen with gp100-plus-high-dose interleukin-2, as compared with interleukin-2 alone.23
Although gp100 appeared to attenuate ipilimu
mab responses in our study, it is important to
consider the fact that some radiographic responses of immunotherapeutic agents are not
captured by standard response criteria.34 Regardless, such effects of gp100 did not translate into
a difference in overall survival between the two
ipilimumab groups.
The data in this study are consistent with the
results of phase 2 trials of ipilimumab monotherapy in the same patient population.15-17 The
data from phase 2 studies suggest that there is
a long-term survival effect of ipilimumab monotherapy; ipilimumab monotherapy at a dose of
3 mg per kilogram resulted in 1-year and 2-year
survival rates of 39.3% and 24.2%, respectively.16
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338 (88.9)

Any drug-related event

75 (19.7)
67 (17.6)

Abdominal pain
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5 (1.3)
0

67 (17.6)

Rash

2 (0.5)
3 (0.8)

Hypophysitis

Adrenal insufficiency

1 (0.3)

6 (1.6)
3 (0.8)

4 (1.1)

15 (3.9)

Hypothyroidism

11 (2.9)

20 (5.3)

Colitis

Endocrine

Hypopituitarism

14 (3.7)

115 (30.3)

Diarrhea

2 (0.5)

2 (0.5)

2 (0.5)

20 (5.3)

14 (3.7)
122 (32.1)

Vitiligo

Gastrointestinal

0

0

0

0

0

1 (0.3)

0

2 (0.5)

0

0

2 (1.5)

2 (1.5)

3 (2.3)

2 (1.5)

10 (7.6)

10 (7.6)

36 (27.5)

38 (29.0)

3 (2.3)

25 (19.1)

32 (24.4)

57 (43.5)

80 (61.1)

15 (11.5)

19 (14.5)

21 (16.0)

19 (14.5)

16 (12.2)

35 (26.7)

55 (42.0)

20 (15.3)

31 (23.7)

27 (20.6)

46 (35.1)

43 (32.8)

105 (80.2)

0

2 (1.5)

1 (0.8)

0

3 (2.3)

7 (5.3)

6 (4.6)

10 (7.6)

0

1 (0.8)

0

2 (1.5)

16 (12.2)

4 (3.1)

4 (3.1)

0

3 (2.3)

0

2 (1.5)

9 (6.9)

2 (1.5)

3 (2.3)

3 (2.3)

3 (2.3)

7 (5.3)

25 (19.1)

49 (37.4)

0

0

1 (0.8)

0

2 (1.5)

0

0

0

0

0

0

0

3 (2.3)

0

1 (0.8)

0

0

0

0

0

0

0

0

0

0

5 (3.8)

11 (8.4)

number of patients (percent)
127 (96.9)

0

0

0

2 (1.5)

2 (1.5)

1 (0.8)

18 (13.6)

19 (14.4)

1 (0.8)

6 (4.5)

14 (10.6)

22 (16.7)

42 (31.8)

23 (17.4)

25 (18.9)

18 (13.6)

19 (14.4)

23 (17.4)

29 (22.0)

41 (31.1)

22 (16.7)

29 (22.0)

34 (25.8)

52 (39.4)

26 (19.7)

104 (78.8)

128 (97.0)

Total

0

0

0

0

0

0

1 (0.8)

1 (0.8)

0

0

0

0

4 (3.0)

11 (8.3)

6 (4.5)

0

3 (2.3)

2 (1.5)

3 (2.3)

4 (3.0)

6 (4.5)

3 (2.3)

1 (0.8)

3 (2.3)

1 (0.8)

15 (11.4)

54 (40.9)

Grade 3

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

1 (0.8)

0

1 (0.8)

0

0

0

0

0

8 (6.1)

Grade 4

of

0

1 (0.3)

2 (0.5)

0

2 (0.5)

0

0

0

1 (0.3)

0

0

1 (0.3)

0

1 (0.3)

1 (0.3)

4 (1.1)

26 (6.8)

Grade 4

gp100 Alone (N = 132)
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1 (0.3)

67 (17.6)

Pruritus

8 (2.1)

152 (40.0)

37 (9.7)

11 (2.9)

12 (3.2)

1 (0.3)

4 (1.1)

2 (0.5)

5 (1.3)

19 (5.0)

6 (1.6)

6 (1.6)

3 (0.8)

5 (1.3)

16 (4.2)

62 (16.3)

147 (38.7)

Dermatologic

221 (58.2)

41 (10.8)

Any immune-related event

46 (12.1)

55 (14.5)

Cough

Anemia

65 (17.1)

Headache

Dyspnea

88 (23.2)
78 (20.5)

Decreased appetite

Pyrexia

137 (36.1)

Fatigue

Other

81 (21.3)

Vomiting

129 (33.9)

Nausea

Constipation

146 (38.4)

Diarrhea

Gastrointestinal disorders

374 (98.4)

Grade 3

Total

Grade 4

Total

Grade 3

Ipilimumab Alone (N = 131)

Ipilimumab plus gp100 (N = 380)

Any event

Adverse Event

Table 3. Adverse Events in the Safety Population.*
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* The adverse events listed here were reported in at least 15% of patients. The most common immune-related adverse events and those of particular clinical relevance are also listed.
Patients could have more than one adverse event. Included are all patients who received at least one dose of a study drug (643 patients). A total of 14 deaths (2.2%) were determined
by the investigators to be related to the study drug (8 in the ipilimumab-plus-gp100 group, 4 in the ipilimumab-alone group, and 2 in the gp100-alone group). Seven of the 14 deaths
related to the study drug were associated with immune-related adverse events: 5 in the ipilimumab-plus-gp100 group (1 patient had grade 3 colitis and septicemia; 3 patients had bowel perforation–inflammatory colitis, bowel perforation, or multiorgan failure–peritonitis; and 1 patient had Guillain–Barré syndrome, which is considered to be consistent with a neurologic immune-related adverse event) and 2 in the ipilimumab-alone group (1 patient had colic bowel perforation and the other had liver failure). Deaths related to the study drug that
were not associated with immune-related adverse events included deaths from sepsis, myelofibrosis, and acute respiratory distress syndrome (3 patients in the ipilimumab-plus-gp100
group); severe infection–renal failure–septic shock, and vascular leak syndrome (2 patients in the ipilimumab-alone group), and cachexia and septic shock (2 patients in the gp100alone group).

0

0
1 (0.8)

0
0

3 (2.3)
1 (0.8)

0
0

2 (1.5)
6 (4.6)

1 (0.8)
0
1 (0.3)

5 (1.3)

2 (0.5)
Hepatitis

Other

12 (3.2)

0

0

0
0

0
2 (1.5)

3 (2.3)
0

0
0

0
2 (1.5)

1 (0.8)
0

0

1 (0.3)
4 (1.1)
Increase in aspartate aminotransferase

2 (0.5)
3 (0.8)
Increase in alanine aminotransferase

0

0
0

3 (2.3)
6 (4.5)

0
1 (0.8)

0
0

0
2 (1.5)

5 (3.8)
0
4 (1.1)
8 (2.1)

0
0
0
Decrease in serum corticotropin level

Hepatic

0
2 (0.5)
Increase in serum thyrotropin level

0

1 (0.8)

0

0

0

0

0
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The long-term effect of ipilimumab in our study
is shown by survival analyses at late time points,
which showed 1-year and 2-year survival rates of
45.6% and 23.5%, respectively. In recent, randomized, phase 3 trials involving patients with
unresectable stage III or IV melanoma who had
received previous treatment, 1-year survival rates
were reported to be 22% to 38% with various
treatment regimens.35,36 The median overall survival in these studies ranged from 5.9 to 9.7
months. Neither these nor other randomized,
controlled trials had shown a significant improvement in overall survival.
The adverse-event profile of ipilimumab in
this study is consistent with that reported in
phase 2 trials,15-17 with the majority of adverse
events being immune-related and consistent
with the proposed mechanism of action of ipi
limumab.11-14 As shown in phase 2 studies,
prompt medical attention and early administration of corticosteroids are critical to the management of immune-related adverse events.15-17
Management guidelines (algorithms) for immunerelated adverse events involve close patient followup and the administration of high-dose systemic
corticosteroids — which were used as necessary
in our study — for grade 3 or 4 events.37,38
In conclusion, this randomized, controlled
trial showed that there was a significant improvement in overall survival among patients with
metastatic melanoma. In some patients, side effects can be life-threatening and may be treatment-limiting. Reinduction with ipilimumab at
the time of disease progression can result in further clinical benefit. Overall, our findings suggest
that the T-cell potentiator ipilimumab may be useful as a treatment for patients with metastatic
melanoma whose disease progressed while they
were receiving one or more previous therapies.
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